BACKGROUND AND PURPOSE: @entity7102 -induced clots used in experimental @entity64 differ from clots forming spontaneously under clinical conditions. We investigated whether this difference influences the efficacy and outcome of thrombolytic treatment. METHODS: In @entity35 , the middle cerebral artery was occluded by intracarotid injection of fibrin-rich clots, prepared either according to established methods by adding @entity7102 to freshly drawn arterial blood or by spontaneous coagulation. The mechanical properties of clots were determined in vitro by elasticity and plasticity tests. One hour after @entity887 , thrombolysis was started by intra-arterial application of recombinant tissue plasminogen activator (rtPA) (10 mg/kg). Treatment efficacy was monitored by MR measurements of blood perfusion, @entity1541 ( @entity1541 ), T2 relaxation time and blood-brain barrier permeability, and by pictorial measurements of @entity855 and pH. RESULTS: @entity7102 -induced clots were classified as elastic, and spontaneously forming clots were classified as plastic. @entity2500 with @entity7102 -induced or spontaneously forming clots led to similar reduction of perfusion and @entity1541 , but rtPA treatment efficacy differed greatly. In the spontaneously forming clot group, blood perfusion returned to or above control within 2 hours, @entity1541 and @entity855 normalized, tissue pH exhibited @entity5838 , and T2 and blood-brain barrier permeability did not change. In the @entity7102 -induced clot group, in contrast, blood reperfusion was delayed, @entity1541 and @entity855 remained reduced, tissue pH was acidic, and @entity4 developed, as reflected by increased T2 and blood-brain barrier permeability. CONCLUSIONS: rtPA-induced thrombolysis promotes rapid reperfusion and tissue recovery in animals embolized with spontaneously forming clots but not in those embolized with @entity7102 -induced clots. This difference is explained by the different mechanical and possibly molecular consequences of clot preparation and must be considered for the interpretation of thrombolysis experiments.

Differences in clot preparation determine outcome of recombinant tissue plasminogen activator treatment in experimental XXXX .

@entity5838 :: ('MESH:D000471', 'Disease') :: ['alkalosis'] @entity64 :: ('MESH:D020521', 'Disease') :: ['thromboembolic stroke'] @entity2500 :: ('MESH:D020244', 'Disease') :: ['Middle cerebral artery embolism'] @entity4 :: ('MESH:D004487', 'Disease') :: ['edema'] @entity1541 :: ('MESH:C536023', 'Disease') :: ['ADC', 'apparent diffusion coefficient'] @entity887 :: ('MESH:D004617', 'Disease') :: ['embolism'] @entity7102 :: ('29251(Tax:10116)', 'Gene') :: ['Thrombin', 'thrombin'] @entity35 :: ('10116', 'Species') :: ['rats'] @entity855 :: ('MESH:D000255', 'Chemical') :: ['ATP']
@entity64 :: (MESH:D020521,Disease) :: ['thromboembolic stroke']
